Nifty
Sensex
:
:
10772.05
35510.10
-49.80 (-0.46%)
-179.50 (-0.50%)

Pharmaceuticals & Drugs

Rating :
67/99

BSE: 532296 | NSE: GLENMARK

606.45
6.60 (1.10%)
25-Jun-2018 | 2:44PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  601.35
  •  613.95
  •  600.05
  •  599.85
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1375768
  •  8343.35
  •  746.00
  •  493.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 16,925.86
  • 21.06
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 20,593.15
  • 0.33%
  • 3.28

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.54%
  • 2.69%
  • 11.36%
  • FII
  • DII
  • Others
  • 2.78%
  • 3.64%
  • 32.99%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Sep 17
Sep 16
Var%
Jun 17
Jun 16
Var%
Net Sales
2,279.82
2,457.18
-7.22%
2,203.66
2,535.01
-13.07%
2,256.59
2,224.11
1.46%
2,363.00
1,943.05
21.61%
Expenses
1,952.98
2,013.34
-3.00%
1,880.97
1,769.98
6.27%
1,868.19
1,775.34
5.23%
1,785.55
1,563.98
14.17%
EBITDA
326.83
443.84
-26.36%
322.69
765.02
-57.82%
388.40
448.77
-13.45%
577.45
379.07
52.33%
EBIDTM
14.34%
18.06%
14.64%
30.18%
17.21%
20.18%
24.44%
19.51%
Other Income
69.55
-51.29
-
-23.16
14.57
-
29.73
-1.84
-
15.29
75.92
-79.86%
Interest
74.39
69.67
6.77%
70.47
61.74
14.14%
69.84
62.87
11.09%
70.86
43.04
64.64%
Depreciation
73.53
68.90
6.72%
75.38
62.53
20.55%
75.23
68.70
9.51%
77.73
64.23
21.02%
PBT
248.47
173.03
43.60%
153.67
655.33
-76.55%
273.05
315.36
-13.42%
444.14
347.71
27.73%
Tax
96.84
-10.73
-
48.93
178.23
-72.55%
58.93
91.77
-35.79%
110.76
120.93
-8.41%
PAT
151.63
183.76
-17.48%
104.74
477.10
-78.05%
214.12
223.58
-4.23%
333.38
226.78
47.01%
PATM
6.65%
7.48%
4.75%
18.82%
9.49%
10.05%
14.11%
11.67%
EPS
5.37
6.51
-17.51%
3.71
16.91
-78.06%
7.59
7.92
-4.17%
11.81
8.04
46.89%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Net Sales
9,103.07
9,079.41
7,561.67
6,680.94
5,944.95
4,969.14
4,020.64
2,949.07
2,480.46
2,086.48
1,975.71
Net Sales Growth
-0.61%
20.07%
13.18%
12.38%
19.64%
23.59%
36.34%
18.89%
18.88%
5.61%
 
Cost Of Goods Sold
3,038.57
2,552.03
2,246.58
1,538.25
1,785.62
1,584.70
1,291.00
951.07
784.28
658.07
472.22
Gross Profit
6,064.50
6,527.39
5,315.09
5,142.69
4,159.33
3,384.44
2,729.65
1,998.00
1,696.18
1,428.41
1,503.48
GP Margin
66.62%
71.89%
70.29%
76.98%
69.96%
68.11%
67.89%
67.75%
68.38%
68.46%
76.10%
Total Expenditure
7,487.69
7,042.71
6,124.52
5,466.62
4,854.17
3,953.86
3,306.28
2,356.82
1,860.89
1,631.50
1,175.18
Power & Fuel Cost
-
127.02
120.47
109.11
93.50
80.13
0.00
0.00
31.86
25.55
19.48
% Of Sales
-
1.40%
1.59%
1.63%
1.57%
1.61%
0%
0%
1.28%
1.22%
0.99%
Employee Cost
-
1,640.81
1,378.19
1,212.61
1,026.15
782.95
628.89
510.17
289.95
272.34
173.54
% Of Sales
-
18.07%
18.23%
18.15%
17.26%
15.76%
15.64%
17.30%
11.69%
13.05%
8.78%
Manufacturing Exp.
-
1,044.48
956.59
1,323.66
336.59
272.53
54.40
40.76
142.80
156.13
154.22
% Of Sales
-
11.50%
12.65%
19.81%
5.66%
5.48%
1.35%
1.38%
5.76%
7.48%
7.81%
General & Admin Exp.
-
525.16
491.20
253.29
859.67
678.94
1,331.99
854.82
268.51
258.24
175.40
% Of Sales
-
5.78%
6.50%
3.79%
14.46%
13.66%
33.13%
28.99%
10.83%
12.38%
8.88%
Selling & Distn. Exp.
-
1,064.70
892.67
991.23
524.25
521.00
0.00
0.00
310.32
254.38
171.85
% Of Sales
-
11.73%
11.81%
14.84%
8.82%
10.48%
0%
0%
12.51%
12.19%
8.70%
Miscellaneous Exp.
-
88.52
38.82
38.48
228.40
33.61
0.00
0.00
33.15
6.79
171.85
% Of Sales
-
0.97%
0.51%
0.58%
3.84%
0.68%
0%
0%
1.34%
0.33%
0.43%
EBITDA
1,615.37
2,036.70
1,437.15
1,214.32
1,090.78
1,015.28
714.36
592.25
619.57
454.98
800.53
EBITDA Margin
17.75%
22.43%
19.01%
18.18%
18.35%
20.43%
17.77%
20.08%
24.98%
21.81%
40.52%
Other Income
91.41
37.37
20.00
6.88
11.48
10.75
18.17
144.41
50.45
179.26
53.69
Interest
285.56
237.32
178.88
190.15
188.59
160.01
146.57
160.46
165.50
145.72
71.04
Depreciation
301.87
264.37
234.28
300.41
216.79
127.01
97.88
94.68
120.61
102.68
71.68
PBT
1,119.33
1,572.38
1,043.98
730.63
696.88
739.00
488.09
481.54
383.90
385.84
711.50
Tax
315.46
382.68
300.94
334.07
151.27
110.72
23.78
23.70
52.87
75.41
79.39
Tax Rate
28.18%
25.66%
28.83%
61.46%
21.71%
14.98%
4.87%
4.92%
13.77%
28.04%
11.16%
PAT
803.87
1,108.80
743.23
209.54
542.27
620.03
460.35
453.20
324.47
191.66
632.13
PAT before Minority Interest
803.79
1,108.75
743.04
209.47
545.60
628.29
464.31
457.83
331.03
193.47
632.11
Minority Interest
-0.08
0.05
0.19
0.07
-3.33
-8.26
-3.96
-4.63
-6.56
-1.81
0.02
PAT Margin
8.83%
12.21%
9.83%
3.14%
9.12%
12.48%
11.45%
15.37%
13.08%
9.19%
32.00%
PAT Growth
-27.66%
49.19%
254.70%
-61.36%
-12.54%
34.69%
1.58%
39.67%
69.29%
-69.68%
 
Unadjusted EPS
28.48
39.29
26.47
7.72
20.01
22.91
17.03
16.78
12.40
7.70
25.80

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Shareholder's Funds
4,492.52
3,629.64
1,783.49
2,983.28
2,763.03
2,401.63
2,037.24
2,355.23
1,598.16
1,517.87
Share Capital
28.22
28.22
27.13
27.12
27.09
27.05
27.03
26.98
25.05
24.87
Total Reserves
4,462.86
3,599.98
1,756.36
2,956.16
2,735.94
2,374.58
2,010.21
2,328.25
1,573.10
1,493.00
Non-Current Liabilities
3,257.81
1,499.40
2,749.09
1,966.58
1,625.13
1,137.64
519.01
1,940.41
2,151.27
1,085.49
Secured Loans
0.00
0.00
0.00
2,428.66
1,920.30
1,312.47
617.07
241.41
382.65
196.13
Unsecured Loans
4,536.34
2,487.30
2,574.38
0.00
0.00
0.00
0.00
1,627.98
1,711.69
794.81
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
14.58
6.90
0.00
0.00
0.00
Current Liabilities
2,702.68
3,999.25
3,776.71
2,949.17
2,201.39
1,901.74
2,259.06
518.62
456.33
320.72
Trade Payables
1,903.52
1,940.79
1,948.04
1,362.58
1,036.94
788.83
657.41
379.27
343.48
230.79
Other Current Liabilities
509.32
1,137.01
1,264.30
973.31
763.41
414.83
109.80
119.38
96.41
72.17
Short Term Borrowings
187.19
787.42
347.60
353.32
367.82
687.46
1,480.23
0.00
0.00
0.00
Short Term Provisions
102.65
134.03
216.78
259.95
33.22
10.63
11.62
19.97
16.44
17.76
Total Liabilities
10,452.59
9,127.99
8,309.10
7,912.31
6,613.91
5,466.01
4,842.01
4,827.27
4,208.92
2,925.56
Net Block
2,755.09
2,593.55
2,015.38
2,889.66
2,406.26
2,237.30
2,066.62
1,787.31
1,566.24
918.51
Gross Block
4,769.92
4,300.54
3,495.47
3,632.62
2,934.90
2,650.96
2,383.39
2,175.54
1,838.58
1,124.10
Accumulated Depreciation
2,014.83
1,706.99
1,480.09
742.96
528.63
413.66
316.77
388.23
272.33
205.59
Non Current Assets
3,577.96
3,223.69
2,978.04
3,149.61
2,887.10
2,518.85
2,243.24
2,406.20
2,129.78
1,274.56
Capital Work in Progress
708.11
542.79
477.13
206.24
422.31
248.33
145.70
600.77
545.41
337.23
Non Current Investment
15.69
17.20
17.12
0.00
0.00
0.00
0.00
18.12
18.12
18.82
Long Term Loans & Adv.
98.94
69.99
468.16
33.39
36.52
0.00
0.00
0.00
0.00
0.00
Other Non Current Assets
0.13
0.16
0.27
20.33
22.00
33.23
30.92
0.00
0.00
0.00
Current Assets
6,874.64
5,904.30
5,331.06
4,762.69
3,726.81
2,947.15
2,598.77
2,421.07
2,079.14
1,651.00
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,139.05
1,567.76
1,269.04
932.88
843.53
787.67
807.01
708.46
630.23
400.74
Sundry Debtors
2,404.32
2,492.65
2,511.76
2,156.34
1,640.05
1,243.61
1,130.81
1,078.28
955.34
806.85
Cash & Bank
1,056.36
857.12
775.88
800.67
607.31
321.92
195.83
107.02
71.48
156.51
Other Current Assets
1,274.90
391.88
31.44
104.37
635.91
593.95
465.11
527.31
422.09
286.90
Short Term Loans & Adv.
775.74
594.89
742.94
768.44
540.03
518.90
322.39
527.31
422.09
286.90
Net Current Assets
4,171.96
1,905.05
1,554.35
1,813.53
1,525.42
1,045.41
339.71
1,902.45
1,622.81
1,330.28
Total Assets
10,452.60
9,127.99
8,309.10
7,912.30
6,613.91
5,466.00
4,842.01
4,827.27
4,208.92
2,925.56

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Cash From Operating Activity
657.43
344.85
481.68
853.73
647.93
804.39
930.58
352.40
15.91
371.78
PBT
1,491.43
1,043.98
543.54
696.88
739.00
488.09
481.55
383.90
268.88
711.50
Adjustment
726.56
391.03
522.76
709.78
342.45
484.05
189.65
265.26
274.15
133.39
Changes in Working Capital
-861.51
-611.96
-266.82
-290.07
-268.49
-34.79
353.13
-209.36
-387.66
-384.56
Cash after chg. in Working capital
1,356.48
823.05
799.49
1,116.58
812.96
937.35
1,024.34
439.80
155.37
460.33
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-699.05
-478.20
-317.81
-262.86
-165.03
-132.96
-93.75
-87.40
-139.46
-88.55
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-712.35
-880.17
-540.04
-368.10
-464.06
-277.79
-367.27
-386.91
-950.16
-509.62
Net Fixed Assets
-256.09
-286.93
-1,354.84
-112.12
-178.05
-54.88
-40.77
-52.58
406.38
-188.35
Net Investments
-8.28
-198.90
-250.28
-114.91
-211.06
-42.02
-48.33
-755.29
-40.93
-57.60
Others
-447.98
-394.34
1,065.08
-141.07
-74.95
-180.89
-278.17
420.96
-1,315.61
-263.67
Cash from Financing Activity
543.15
698.60
199.22
-98.02
195.24
-361.39
-435.61
70.05
849.23
188.58
Net Cash Inflow / Outflow
488.24
163.27
140.86
387.61
379.11
165.21
127.70
35.54
-85.02
50.75
Opening Cash & Equivalents
857.12
763.74
794.80
605.18
320.08
194.87
103.58
71.48
156.51
105.75
Closing Cash & Equivalent
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87
107.02
71.48
156.51

Financial Ratios

Consolidated /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Book Value (Rs.)
159.16
128.59
65.74
109.99
102.01
88.77
75.38
87.28
63.79
61.03
ROA
11.33%
8.52%
2.58%
7.51%
10.40%
9.01%
9.47%
7.33%
5.42%
26.01%
ROE
27.31%
27.46%
8.79%
18.99%
24.33%
20.92%
20.85%
16.75%
12.42%
57.35%
ROCE
20.54%
18.53%
12.40%
15.04%
17.67%
14.44%
15.34%
13.88%
13.37%
37.88%
Fixed Asset Turnover
2.03
1.96
1.90
1.83
1.79
1.60
1.29
1.25
1.43
2.19
Receivable days
97.29
119.39
125.97
115.37
104.99
107.78
136.71
148.42
151.98
124.70
Inventory Days
73.65
67.68
59.42
53.99
59.39
72.38
93.78
97.70
88.92
60.90
Payable days
98.59
117.03
95.22
83.15
68.48
108.47
106.73
68.48
62.10
61.26
Cash Conversion Cycle
72.35
70.04
90.17
86.21
95.91
71.69
123.76
177.63
178.80
124.34
Total Debt/Equity
1.05
1.10
2.13
1.10
1.00
0.93
1.03
0.79
1.31
0.65
Interest Cover
7.28
6.84
3.86
4.70
5.62
4.33
4.00
3.32
2.85
11.02

News Update:


  • USFDA approves ANDA for Glenmark Pharma’s manufacturing facility in Monroe
    19th Jun 2018, 09:14 AM

    The approval is for Atovaquone and Proguanil Hydrochloride Tablets

    Read More
  • Glenmark receives USFDA's approval for generic version of Loestrin
    6th Jun 2018, 15:19 PM

    According to IQVIA sales data for the 12 month period ending April 2018, the Loestrin 21 1.5/30 Tablets market achieved annual sales of approximately $24.2 million

    Read More
  • Glenmark gets nod to acquire 100% stake in Zorg
    30th May 2018, 09:15 AM

    The meeting of the Board of Directors of the company held on May 29, 2018, approved the same

    Read More
  • Glenmark submits New Drug Application for Ryaltris to USFDA
    22nd May 2018, 09:17 AM

    Ryaltris an investigational fixed-dose combination nasal spray of an antihistamine and a steroid

    Read More
  • Glenmark receives ANDA approval for Colesevelam Hydrochloride Tablets
    21st May 2018, 09:10 AM

    The company has already commenced supplies of the product to the US market

    Read More
  • Glenmark Pharmaceuticals presents Phase 2a data on GBR 830
    18th May 2018, 09:03 AM

    The exploratory Phase 2a study was conducted to investigate the safety of GBR 830, evaluate its effects on AD biomarkers

    Read More
  • Glenmark launches generic Seretide Accuhaler in Denmark
    16th May 2018, 09:03 AM

    This is Glenmark’s first inhaled respiratory product launch in Europe

    Read More
  • Glenmark receives ANDA approval for generic version of Temovate Cream
    11th May 2018, 08:57 AM

    The Temovate Cream, 0.05% market achieved annual sales of approximately $118.0 million

    Read More
  • Glenmark Pharmaceuticals to showcase new, updated data on GBR 830
    10th May 2018, 10:12 AM

    The company will be presenting new and updated data on GBR 830 at the upcoming IID meeting in Orlando, Florida

    Read More
  • Glenmark receives ANDA approval for generic Temovate Topical Solution
    20th Apr 2018, 09:01 AM

    The Temovate Topical Solution, 0.05% market2 achieved annual sales of approximately $46.2 million

    Read More
  • Glenmark receives ANDA approval for generic Protopic Ointment
    18th Apr 2018, 09:01 AM

    The Protopic Ointment, 0.1% market2 achieved annual sales of approximately $109.0 million

    Read More
  • Glenmark Pharmaceuticals initiates Phase 2b clinical trial of GBR 830
    17th Apr 2018, 09:03 AM

    The trial’s primary endpoint will assess the efficacy of GBR 830, compared to placebo

    Read More
  • Glenmark recalls over 1 lakh bottles of Indomethacin capsules from US market
    6th Apr 2018, 15:54 PM

    The recall is due to incorrect instructions on the labeling

    Read More
  • Glenmark, Helsinn enter into licensing agreement to launch AKYNZEO in India, Nepal
    4th Apr 2018, 15:24 PM

    The licensing agreement with Glenmark for AKYNZEO represents Helsinn’s first such agreement in India

    Read More
  • Glenmark receives ANDA approval for Clobetasol Propionate Spray
    27th Mar 2018, 08:58 AM

    This product will be manufactured at Glenmark’s Baddi plant in India

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.